Evaluation of appropriate nutrient intake for patients treated with sodium-glucose-cotransporter-2 inhibitor.

Evaluation of appropriate nutrient intake for patients treated with sodium-glucose-cotransporter-2 inhibitor. - Effect of SGLT2 inhibitor on nutrient intake

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025536

Enrollment

Registered

2017-01-14

Start date

2015-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes

Interventions

administiration of dapagliflozin(5mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatient treatment at our medical center

Exclusion criteria

Exclusion criteria: 1. Patients with hypersensitivity to Dapaglifozin 2. Type1 diabetes 3. Subjects with severe ketosis,diabetic coma or precoma 4. Subjects with severe infection,befor and after surgery or severe injury 5. Pregnancy 6. Past history of acute coronary syndrome 7. Malignancy 8. Patients who attending physicians consider to be inappropriate due to other reasons mentioned above

Design outcomes

Primary

Measure	Time frame
Nutrient intake (at 0.4.12 weeks after administration, estimated by brief-type self-administered diet history questionnaire) Body composition(at 0.12 weeks after administration, calculated by DEXA)	—

Secondary

Measure	Time frame
Fasting plasma glucose,GA,HbA1c Liver function,renal function,serum keton body, lipid level,serum glucagon,C-peptide Blood pressure,body weight,etc.	—

Countries

Japan

Contacts

Public ContactRieko Kosugi

Shizuoka General Hospital Center of Diabetes and endoclinology

fwkh7040spring@yahoo.co.jp054-247-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026